Combinatorx, Incorporated

Zalicus, Inc.

Indus Pharmaceuticals, Inc.

Palaniyandi Manivasakam

Edward Roydon Jost-Price

Alexis Borisy

Curtis Keith

Nicole Hurst

Grant R Zimmermann

Michael Andrew Foley

Robyn Sackeyfio

Jason Fong

Michael S Slavonic

Brendan Smith

Benjamin A Auspitz

Pravin R Chaturvedi

Sharon Cantor

Steven Grossman

Grant Zimmerman

Michael A Foley

The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent.

Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

Methods and reagents for the treatment of immunoinflammatory disorders

The invention features pharmaceutical compositions that include dipyridamole and a corticosteroid.

Combinations for the treatment of immunoinflammatory disorders

The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.

Methods and reagents for the treatment of inflammatory disorders

The invention features methods and compositions for the treatment of immunonflammatory disorders.

Combinations for the treatment of inflammatory disorders

The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit immunoinflammation.

The invention features a pharmaceutical composition that includes amoxapine and a corticosteroid.

The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit inflammation.

Growing community of inventors

Brighton, MA, United States of America

Palaniyandi Manivasakam